Drugs / AAB-003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01369225 | Jul 2011 → Aug 2014 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01193608 | Sep 2010 → Oct 2013 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAB-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01193608 ↗ |
| Known as | PF-05236812 | “This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease.” NCT01369225 ↗1“This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease.” NCT01193608 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody to amyloid β” PMID 26925577 ↗ Mar 2016 |
| Route | Intravenous | “after intravenous infusions of escalating doses” PMID 26925577 ↗ Mar 2016 |